Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matria Healthcare (MATR) -- Ignore unavailable to you. Want to Upgrade?

To: Gregory Cole Brock who wrote (139)	4/22/1998 7:58:00 AM
From: Tony Harper	Respond to of 220

Anyone out there with info please post it. I heard about the J&J drug not being approved but that should not cause this kind of a drop. Does anyone have access to a level 2 terminal. If so is this large block sells or bunches of small ones? Is someone accumilating cheap? Tony

To: Gregory Cole Brock who wrote (139)	4/22/1998 8:40:00 PM
From: GREATMOOD	Read Replies (1) \| Respond to of 220

Greg, I can't begin to tell you how disgusted I am. I am still in shock over the FDA decision re: Johnson & Johnson's antocin. This company has been in a war with a segment of the ob/gyn community, and, either directly or indirectly, they seem to have lost every battle. I think antocin was to become a very important component of Matria's future earnings because of the controversy surrounding terbutalene. Matria has lost some of their terbutalene business because of the FDA letter that went out to physician's in response to the NWHN. The street was expecting the approval of antocin, and when it didn't happen, they sold the heck out of the stock. The future of Matria now lies in the hands of their management. They have seen the writing on the wall for months now, and have started to reinvent the company. They have already begun to diversify into less controversial markets. Their diabetes business is doing well and growing, but the question I have is how long it will take for their new businesses to not only replace the loss in terbutalene revenues, but to grow the yearly EPS. They must find other sources of revenues if we are ever going to make a profit from our investment. We were told that they are going to add the management of other disease states to the mix and become a "one stop shop" healthcare company. This sounds positive, but my question is when will this happen? I sure hope they do something soon. I was looking for the stock to be in the 8s after the approval of antocin. Instead, we are in the mid 4s, and it hurts! Earnings are coming out this week on Friday. I am waiting to hear what they have to say about their terbutalene business and how they plan to replace lost revenues and grow future earnings. The other question I have is when and at what price we will see the share buyback begin. GM